Form 4: CytomX Therapeutics CFO Christopher Ogden Reports Stock and Option Awards

Christopher Ogden, CFO of CytomX Therapeutics, reports the acquisition of restricted stock units and stock options.

Summary

• Christopher Ogden, the Chief Financial Officer of CytomX Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On February 4, 2025, Ogden acquired 44,000 restricted stock units (RSUs) that vest annually starting March 15, 2026.
• Ogden also acquired 57,500 RSUs that vest 50% annually starting March 15, 2026.
• Additionally, Ogden acquired options to purchase 225,000 shares of common stock at an exercise price of $0.864, vesting monthly from February 4, 2025, over four years.
• He also acquired options to purchase 115,000 shares of common stock at an exercise price of $0.864, vesting monthly from February 4, 2025, over two years.
• Following these transactions, Ogden beneficially owns 209,577 shares of common stock, including 179,310 RSUs, 225,000 stock options and 115,000 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects standard executive compensation practices, aligning management interests with shareholders through equity ownership. There are no indications of negative events or concerns.

Positives

• The grant of RSUs and stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedules encourage long-term commitment from the CFO.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the RSUs and stock options.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the equity holdings of company insiders. The grants are typical compensation for executives in publicly traded companies, particularly in the biotech industry.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of compensation for executives in biotech companies.
• Vesting schedules are generally structured to incentivize long-term performance and retention, with typical vesting periods ranging from two to four years.

Stakeholder Impact

• The grants align the CFO's interests with shareholders, incentivizing him to increase shareholder value.
• Employees may view the grants as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Form 4, CytomX Therapeutics, CTMX, Christopher Ogden, CFO, restricted stock units, stock options, beneficial ownership